<qa>  What is the primary endpoint of the study?The primary endpoint will be Progression Free Survival measured from the first treatment in this study until progression. Additional endpoints will be Pharmacokinetics of systemic Irinotecan and SN-38 Irinotecan Bead treatment for feasibility group only; Tumor Response measured according to RECIST; Local tumor response extent of necrosis in the treated lesions; hepatic progression free survival measured from first treatment until progression in the liver; change in tumor markers CEA and optional CA19-9; performance status and overall survival assessed by telephone follow-up. Safety will be measured by assessing Adverse Events and Toxicity according to the NCI CTCAE v3.0 criteria. 